SSWM
SUPN icon

Sheets Smith Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Sheets Smith Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-8,671
Closed -$347K – 331
2017
Q3 		$347K Sell
8,671
-88
-1% -$3.81K 0.09% 226
2017
Q2 		$378K Buy
+8,759
New +$312K 0.1% 197
2017
Q1 		– Sell
-36,158
Closed -$913K – 304
2016
Q4 		$913K Sell
36,158
-1,908
-5% -$42.6K 0.26% 107
2016
Q3 		$941K Buy
+38,066
New +$862K 0.27% 105

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Sheets Smith Wealth Management's SUPN Position: Q4 2017 in Review

Sheets Smith Wealth Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2017, closing a stake of 8,671 shares — an estimated $347K sold.

Sheets Smith Wealth Management first reported a position in SUPN in Q3 2016 and held it in 4 quarters. The position peaked at $941K in Q3 2016. 297 funds tracked by Wall St. Rank hold SUPN as of Q4 2017.

  • Sheets Smith Wealth Management reported no remaining Supernus Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Sheets Smith Wealth Management sold 8,671 Supernus Pharmaceuticals shares in Q4 2017, an estimated $347K.
  • Sheets Smith Wealth Management first reported a position in Supernus Pharmaceuticals in Q3 2016 and held it in 4 quarters.
  • Sheets Smith Wealth Management's Supernus Pharmaceuticals position peaked at $941K in Q3 2016.
  • 297 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2017.

Based on Sheets Smith Wealth Management's 13F filing for Q4 2017, filed 12 Jan 2018.